The collaboration leverages Elekta’s digital health interventions platform, Kaiku Health, to facilitate communication between healthcare professionals and their patients on symptom management.
Elekta’s digital solution will provide an accessible, user-friendly way for patients to share relevant information on their well-being with their care team, and to receive tailored support and guidance during treatment.
By utilising machine learning algorithms, the platform will enable real-time evaluation of patient-reported data, providing healthcare providers with personalised insights that may improve patients’ care pathway and care experience.
"We are thrilled to collaborate with Bristol Myers Squibb to potentially advance the use of digital health interventions, such as in the treatment of melanoma," said Anish Patankar, SVP & Head of Business Line Software at Elekta.
“By providing patients with the tools and support they need, we aim to empower them to actively participate in their treatment journey.”
Through personalised symptom monitoring, healthcare professionals can react early and focus on what matters, while enabling their patients to take a more active role in their treatment. In the past 2 years, Elekta has also entered partnerships with Roche and Novartis to deploy digital tools to provide real-time symptom management by patients and healthcare providers.
